Related Experiment Video

Updated: May 17, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Management of docetaxel failures in metastatic castrate-resistant prostate cancer

Sumanta K Pal1, Brian Lewis, Oliver Sartor

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.

The Urologic Clinics of North America
|October 23, 2012
PubMed

Insights

New treatments for metastatic castration-resistant prostate cancer (mCRPC) offer survival benefits. This review details sipuleucel-T, cabazitaxel, and abiraterone efficacy and safety for optimal sequencing post-docetaxel therapy.

Area of Science:

  • Oncology
  • Urology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) treatment has advanced significantly.
  • Docetaxel was a cornerstone, but new agents have emerged, improving patient outcomes.

Purpose of the Study:

  • To review the efficacy and safety of newly approved agents for mCRPC.
  • To provide a clinical framework for sequencing these agents, especially post-docetaxel.

Main Methods:

  • Review of recent Phase III clinical trials.
  • Analysis of efficacy and safety data for sipuleucel-T, cabazitaxel, abiraterone, MDV-3100, and radium-223.

Main Results:

  • Sipuleucel-T, cabazitaxel, and abiraterone are approved with demonstrated benefits.
  • MDV-3100 and radium-223 show survival benefits in Phase III trials, pending approval.
  • Optimal sequencing in the post-docetaxel setting presents a clinical challenge due to overlapping indications.

Conclusions:

  • A growing number of treatment options exist for mCRPC.
  • Physicians require guidance on the best sequence of therapies for individual patients.
  • Understanding the efficacy and safety profiles is crucial for informed treatment decisions.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...